About Us | Contact Us |        
LOGIN OR REGISTER
Course Library

Tailoring Approaches to Management in Patients with Rheumatoid Arthritis: What's New?

Rheumatology
Curriculum:
Tailoring Approaches to Management in Patients with RA: What’s New?
Credits:
1 AMA PRA Category 1 Credit(s) ™
Launch Date:
February 14, 2017
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Rheumatologists

Relevant Terms:

Rheumatoid Arthritis

Vibeke Strand, MD, MACR, FACP

Vibeke Strand, MD, MACR, FACP
Adjunct Clinical Professor
Division of Immunology/Rheumatology
Stanford University School of Medicine
Stanford, CA

Vibeke Strand, MD, MACR, FACP, is an adjunct clinical professor in the Division of Immunology and Rheumatology at Stanford University School of Medicine. She serves as a consultant in clinical research and regulatory affairs to pharmaceutical and biotech companies. She graduated from Swarthmore College with honors, and attended the University of California San Francisco School of Medicine, where she also completed her subspecialty in Rheumatology Fellowship. Dr. Strand was one of eight in the first primary care internal medicine residency at Michigan State University.
 
Dr. Strand has been a clinical rheumatologist for 35 years. Her professional interests include development of outcome measures methodology and clinical and regulatory strategies leading to approval of new agents for treatment of autoimmune diseases. Since 1991, Dr. Strand has led a consulting practice offering clinical research and regulatory expertise.

Dr. Strand has authored more than 330 original publications and reviews and 50 chapters, and has co-edited several books and multiple proceedings. She is a Fellow of the American College of Physicians, a Master of the American College of Rheumatology, serves on the editorial board of multiple journals, and is a member of the Cosmos Club.
1. Utilize appropriate risk-assessment and monitoring tools for RA patients to assess disease activity and direct individualized management decisions
2. Integrate new and emerging IL-6 directed therapies in rheumatoid arthritis for individualized treatment plans based on safety and efficacy data, patient selection data, and the rationale for targeting the IL-6 pathway
3. Incorporate strategies for a collaborative approach to RA care that includes a multidisciplinary team of health professionals and includes patient preferences into treatment selection

PHYSICIAN CONTINUING MEDICAL EDUCATION
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and RMEI Medical Education, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
 
Credit Designation
The University of Cincinnati designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Joint Providership Statement
This CME activity is jointly provided by the University of Cincinnati and RMEI Medical Education, LLC.
 
COMMERCIAL SUPPORT
This activity is supported by an independent educational grant from Genzyme, a Sanofi Company and Regeneron Pharmaceuticals.  

DISCLOSURE OF CONFLICTS OF INTEREST
According to the disclosure policy of the University of Cincinnati College of Medicine, all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interest related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. Disclosure will be made at the time of activity.
 
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
  • Vibeke Strand, MD MD, MACR, FACP, has affiliations with AbbVie, Alder, Amgen Corporation, Anthera, Asana, AstraZeneca, aTyr, Bayer, Biogenldec, Boehringer Ingelheim, BMS, Carbylan, Celgene, Celltrion, CORRONA, Crescendo/Myriad Genetics, EMD Serono, Eupraxia, Genentech, Roche, GlaxoSmithKline, Horizon, Iroko, Janssen, Jazz Pharmaceuticals, Kezar, Kypha, Lilly, Merck, Novartis, Pfizer, Protagen, Regenerion, Samsung, Samumed, Sandoz, SKK, UCB, and XTL (Consulting Fees); AbbVie, Amgen, Anthera, AstaZeneca, Biogenldec, Bayer, BMS, Carbylan, Celltrion, Crescendo, EMDSerono, Genenteche/Roche, GSK, Horizon, Iroko, Janssen, Jazz, Lilly, Merck, Novartis, Pfizer, Protagen, Regeneron, Samsung, Sandoz, Sanofi, and UCB (Advisory Boards).
University of Cincinnati
  • Susan P. Tyler, MEd, CMP, CHCP, CME Director, has no affiliations with commercial interests relative to the content to disclose.
  • Rick E. Ricer, MD, Professor Emeritus, CME Physician Reviewer, has no affiliations with commercial interests relative to the content to disclose.
  • Deborah Cole, BS, Program Coordinator, has no affiliation with commercial interest relative to the content to disclose.
RMEI Medical Education, LLC
  • Sy Schlager, MD, PhD, has no affiliations with commercial interests relative to the content to disclose.
  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests relative to the content to disclose.
  • Nora Hartley has no affiliations with commercial interests relative to the content to disclose.
DISCLAIMER
The opinions expressed during the enduring activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development.
 
DISCLOSURE OF UNLABELED USE
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.
  
Estimated time to complete: 1.0 hour
Medium: Internet

FEE INFORMATION
There is no fee for this educational activity.

HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test and evaluation.
Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. You must score 70% or higher on the post-test to receive credit for this activity. Participants have three attempts to successfully pass the post-test.
 
CONTRACT INFORMATION
Accreditation Support:
Please contact the University of Cincinnati, Continuing Medical Education Department at uccme@uc.edu or call 513-558-7277.
Technical Support:
For any technical issues or issues with your CME Certificate, please visit the support center.
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Schedule an event with a Standardized Patient
×